Hospitals & Diagnostics: Formalising India's Care Delivery
Rising incomes, insurance and lifestyle disease burden are driving formalisation of hospital and diagnostic care.
Market Size
~$100 Bn+ (India healthcare delivery, FY26E)
Growth
~12% CAGR (FY26–30E)
Read
7 min
Published
Jul 2026
Overview
Healthcare delivery in India - hospitals, diagnostics and specialty care - is formalising as incomes rise, insurance penetration deepens and the burden of lifestyle and chronic diseases grows. Organised hospital chains are expanding capacity and clinical specialties, while diagnostic chains consolidate a highly fragmented market. Medical tourism adds an incremental, high-value demand pool.
Hospital economics turn on occupancy, average revenue per occupied bed (ARPOB), case mix and payer mix; scaling profitably requires clinical talent, brand and capital discipline. Diagnostics is scaling through networks, home-collection and asset-light franchising, with pricing pressure from digital-first disruptors. Insurance and government schemes (Ayushman Bharat) are widening the payer base.
The sector combines defensive demand with structural growth, but is capital-intensive (hospitals) and increasingly price-competitive (diagnostics). Brand, clinical outcomes and network density are the durable moats.
Illustrative projection from the report's stated market size (~$100 Bn+ (India healthcare delivery, FY26E)) and growth (~12% CAGR (FY26–30E)).
Key Highlights
- Formalisation of a largely unorganised care market
- ARPOB, occupancy and case mix drive hospital returns
- Diagnostics consolidating amid digital-first pricing pressure
- Insurance and Ayushman Bharat widening the payer base
Growth Drivers
- Rising incomes and health-insurance penetration
- Growing chronic and lifestyle disease burden
- Consolidation of fragmented diagnostics
- Medical tourism and specialty-care demand
Key Players
Investment Outlook
Healthcare delivery offers defensive, structurally growing demand, with hospitals rewarding capital-disciplined expansion and diagnostics rewarding scale and brand. We favour operators with strong ARPOB trends or network density and pricing power.
Key Risks
- Capital intensity and long gestation of new hospitals
- Pricing pressure and regulation in diagnostics
- Clinical-talent shortages and cost inflation
The Neoma View
We favour care-delivery franchises with brand strength and clinical outcomes; capital discipline in hospitals and network scale in diagnostics guide our selection.
Talk to an advisor →All figures are indicative and for information only - not investment advice or a recommendation. Market sizes, growth rates and financial metrics are hedged estimates that vary by source and period. Please consult your advisor before investing.
More in Healthcare
Digital Health & Telemedicine
Digital Health & Telemedicine: The Long Road to Scalable Profitability in India's Fragmented Healthcare Landscape
India's digital health sector is poised for substantial growth, driven by increasing internet penetration and a demand for accessible healthcare, yet faces a complex path to sustained profitability amidst intense competition and evolving regulations.
CDMO & Pharma Contract Manufacturing
CDMO & Pharma Contract Manufacturing: India's Ascent in Complex Molecules and Global Supply Chains
India's CDMO sector is poised for robust growth, driven by global outsourcing trends, increasing R&D complexity, and a strategic shift towards higher-value, specialized molecules.
Biosimilars & Biologics
Biosimilars & Biologics: India's Ascent in Complex Biopharmaceuticals - Navigating Global Patent Cliffs and Domestic Demand
India's biopharmaceutical sector is poised for substantial growth, driven by an expanding biosimilar pipeline targeting global patent expiries and increasing domestic demand for advanced biologics, creating a nuanced investment landscape.